Under the conditions of this study, dapsone in doses of 5 mg and 10 mg daily when administered to patients with lepromatous leprosy is an ineffective therapy in terms of killing and elimination of My co. leprae from human skin and bone marrow. A real danger of facilitating the emergence of resistant bacilli exists. Th erefore, until there is more evidence fr om long term therapeutic trials of low dose dapsone in bacillated types of leprosy, conventional dosage of dapsone is recommended.
Clinicians treating lepromatous kprosy patients before and after t1,e iniroduction of sulphones as specific therapy have gained the impression that both the incidence and severity of erythema nodosum leprosum re actions in leprosy have greatly incre ased. There have been reports of the beneficiai effects of low dose DDS in re ducing the incid ence of these reactions in lepromatous leprosy . The apparently effe ctive inhib ition of multiplication of Myco. leprae in the footpads of mice by extremely low concentrations of dapsone in the diet (of the order of 0.000 1 g%) (Shepard et ai., 1966) had tended to breed an undue sense of optimism and confidence in the efficacy of homeopathic doses in mano This optimism was fu rther compounded by extrapolation of reported changes in Morphological lndex of My co. leprae in skin smears to death of Myco. leprae.
A study was initiated to elucidate the pre cise relationship between dose of dapsone and incidence of re actions, as well as the period of viability of My co. leprae in skin and bone marrow of lepromatous leprosy patients on low and high dose of dapsone.
Material and Methods
Thirty consecutive untreated lepromatous leprosy patients were randomly allocated to three therapy groups:
(2) dapsone 10 mg daily ; (3) dapsone 100 mg daily .
Skin smears were taken from 8 standard sites by slit-skin method once a month and Morphological lndex (Shepard and McRae, 196 5) and Bacterial lndex (Ridley, 1964) were determined. Skin biopsy and bone marrow aspiration were obtained immediately prior to initiation of treatment and once in 3 months during the first year and once in 6 months fo r 2 subsequent years. My co. leprae homogenates fram these sp ecimens were injected into hind fo otpads of thymectomized CBA mice which were harvested at regular intervals and harvest counts obtained. ClinicaI records included specific reference to occurrence of ENL, painful neutritis, iritis or any other in tercurrent complication. The reactions were treated with 4 week course of 15 to 30 mg of prednisolone.
Of the 30 patients only 15 patients-5 in each group-completed the study and the data regarding these patients is presented here .
Results

Morphologicallndex
In the majority of cases the MI was between 3 and 10% at ini tiation of treatment and carne down to below 1 % in 12 to 24 weeks in ali the groups. There was no significant difference in rate of fall of MI between the low and the high dose group.
Bacteriallndex
(a) 100 mg dapsone. There was a fa irly uniform fa li in BI at the rate of I + per year. Three of the 5 patients were skin smear nega tive at the end of 3 years. However, in 4 of the 5 patients bone marrow aspirates continued to be positive for My co. leprae.
(b) 10 mg dapsone. In I patient the BI fe ll at the same rate as that seen in patients in 100 mg dapsone. In 2 patients there was no significant change in BI and in 2 patients there was a gradual rise in BI through out the period of therapy despite the MI remaining persistently below the 0.1 % in these cases. Two patients in each of the 3 therapy groups developed ENL and there was no clinically recognizable difference between the 3 groups.
Bacilli in th e bane marrow
Except for I patient on J 00 mg dapsone whose skin smear also had become nega tive at 2 years, in ali the other patients AFB was demonstrable in bone marrow aspirates throughout the period of study.
Viability of Myco. leprae in skin and bane marrow while on th erapy (a) 100 mg dapsane daily. In ali patients, My co. leprae from skin biopsy homogenates were non-viable in fo otpads of mice between 6 and 12 months of treatment with dapsone J 00 mg daily. In 2 the My co. leprae from bone marrow beca me non-viable at 24 months, in I at 3 0 months, in I at 36 months; while in I it was viable at the end of 36 months. (b) 10 mg dapsane daily. In I patient the bacilli from the skin became non-viable at 18 months and in another at 3 6 months while in the rest of the 3 patients the bacilli were still viable at 36 months. However, in alI the patients the bacilli from the bone marrow remained viable at 36 months. (c) 5 mg dapsone daily. In 1 patient the bacilli from the skin became non-viable at 18 months and in another at 36 months. In none of the patients the bacilli from the bone marrow attained non-viability at the end of 36 months (Table 5) . 
Comments
(I) There is no evidence to show that ENL reactions can be reduced by re duction of dosage of dapsone. The occurrence of 'reactions in lepromatous leprosy seems to fo llow an "ali or none" law as far as dapsone is concerned.
(2) Morphological Index, under the conditions of these experiments, appears to be an unreliable measure of viability of My co. leprae.
(3) Dapsone when administered orally in dosage of 100 mg daily, renders the Myco. leprae in human skin non-viable in 6 to 12 months . However, a significant lag period exists between killing of Myco. leprae in skin and in bone marrow, the latter being viable fo r 12 to 24 mo nths after the bacilli in the skin are dead .
(4) Dapsone when administered in daily doses of 5 mg and 10 mg over a 3 year period is far less effe ctive in both killing and eliminating Myco. leprae from skin and bone marrow.
